Skip to main content

Menu

Martindale: The Complete Drug Reference September 2022 Update

This update contains 11 new monographs. Preparations have been updated for 6 countries.

New monographs:

  • Amivantamab is a recombinant human monoclonal antibody. It is used in the treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
  • Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is used for the prevention of migraine.
  • Avacopan is a complement 5a receptor (C5aR) antagonist that acts as a complement blocker by inhibiting C5a-mediated neutrophil activation and migration. It is used as an adjunct to standard therapy in the treatment of severe, active granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis.
  • Daridorexant is an orexin-receptor antagonist used as a hypnotic in the management of insomnia.
  • Eptinezumab is a recombinant humanised monoclonal antibody that is a calcitonin gene-related peptide antagonist used for the prevention of migraine.
  • Levamlodipine is the S-enantiomer of the calcium-channel blocker amlodipine and is used in the treatment of hypertension.
  • Remimazolam is an ultra-short-acting benzodiazepine used for procedural sedation and for the induction and maintenance of general anaesthesia.
  • Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It is given for the prevention and treatment of migraine.
  • Sotrovimab is a recombinant human monoclonal antibody with antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is used in the treatment of mild to moderate COVID-19 infection in patients who do not require oxygen supplementation and are at increased risk of progressing to severe infection.
  • Tepotinib is an orally-active tyrosine kinase inhibitor that targets mesenchymal-epithelial transition (MET) factor. It is used in the treatment of advanced non-small cell lung cancer with MET exon 14 skipping alterations.
  • Vericiguat is a guanylate cyclase stimulator used in the treatment of heart failure with reduced ejection fraction.

Updated names, synonyms and codes; official standards; official preparations:

  • USP NF 2021, Issue 3
  • PhEur 10.6
  • PhEur 10.5
  • PhEur 10.4
  • ATC codes: Encorafenib, Inotuzumab ozogamicin, Osimertinib, Ribociclib

Proprietary Preparations and Manufacturers updated for the following countries and regions:

  • Japan
  • Poland
  • Spain
  • Sweden
  • UK†
  • USA†

† Countries updated on an ongoing basis